Vaxcyte, Inc (PCVX) Announces Proposed Share and Warrant Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Wall Street ends down as oil prices, Treasury yields rise
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Plug Power COO resigns to join another company
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
January 30, 2024 4:01 PM ESTSAN CARLOS, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering... More
